Search results
Results from the WOW.Com Content Network
For children with MRSA-infected bone or joints, treatment is individualized and long-term. Neonates can develop neonatal pustulosis as a result of topical infection with MRSA. [4] Clindamycin is not approved for the treatment of MRSA infection, but it is still used in children for soft-tissue infections. [4]
Tigecycline is used to treat different kinds of bacterial infections, including complicated skin and structure infections, complicated intra-abdominal infections and community-acquired bacterial pneumonia. [citation needed] Tigecycline is a glycylcycline antibiotic that covers MRSA and Gram-negative organisms:
The primary measure of efficacy for this trial was the overall success (defined as survival, symptom improvement, S. aureus bacteremia bloodstream clearance, no new S. aureus bacteremia complications and no use of other potentially effective antibiotics) at the post-treatment evaluation visit, which occurred 70 days after being randomly ...
Without antibiotic treatment, S. aureus bacteremia has a case fatality rate around 80%. [3] With antibiotic treatment, case fatality rates range from 15% to 50% depending on the age and health of the patient, as well as the antibiotic resistance of the S. aureus strain.
REDUCE MRSA, which stands for Randomized Evaluation of Decolonization vs. Universal Clearance to Eliminate methicillin-resistant Staphylococcus aureus (MRSA), was completed in September 2011. [3] This study determined decolonization with chlorhexidine and mupirocin of all patients without screening was the most effective method of reducing the ...
Once the bacterium has been identified as the cause of the illness, treatment is often in the form of antibiotics and, where possible, drainage of the infected area. However, many strains of this bacterium have become antibiotic resistant ; for those with these kinds of infection, the body's own immune system is the only defense against the ...
A shortage in treatment Strep throat is easily treatable with a widely used antibiotic called amoxicillin, Stevenson said. "Usually within about 24 hours of starting that antibiotic, the patient's ...
The U.S. Food and Drug Administration (FDA) approved dalbavancin in May 2014, for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by certain susceptible bacteria such as Staphylococcus aureus including methicillin-susceptible and methicillin-resistant strains of Streptococcus pyogenes, in intravenous dosage ...